宝莱特(300246) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 242,726,398.90, representing a 9.15% increase compared to CNY 222,377,646.65 in the same period last year[7]. - The net profit attributable to shareholders decreased by 39.47% to CNY 24,603,406.51 from CNY 40,649,383.29 year-on-year[7]. - Basic and diluted earnings per share fell by 39.49% to CNY 0.1684 from CNY 0.2783 in the same quarter last year[7]. - The company reported a decrease in total profit of 23.03 million yuan, a decline of 45.70% compared to the previous year[1]. - The total comprehensive income for Q1 2021 was CNY 24,369,934.22, down from CNY 43,030,948.68 in the previous year[44]. - The net profit for the first quarter of 2021 was CNY 20,456,722.59, a decrease of 30.5% compared to CNY 29,382,632.99 in the same period last year[47]. - Operating profit for the first quarter was CNY 21,603,972.41, down from CNY 34,125,207.43 year-over-year, reflecting a decline of 36.6%[47]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -26,201,054.46, a decline of 159.20% compared to CNY 44,261,210.16 in the previous year[7]. - The company reported a cash inflow from investment activities of CNY 52,199,200.00, up from CNY 30,540,821.92 in the same period last year[51]. - The cash flow from financing activities showed a net increase of CNY 1,445,008.46, compared to a net decrease of CNY -2,887,233.16 in the previous year[52]. - The company incurred credit impairment losses of CNY 70,742.91, compared to a loss of -70,858.58 in the previous period[47]. - The cash inflow from investment activities totaled 77,335,646.00 CNY, compared to 30,654,393.92 CNY in the previous period[55]. - The company reported a cash increase of 53,938,072.77 CNY during the period[55]. Expenses and Investments - Research and development expenses increased by 71.84% to 14.91 million yuan, reflecting the company's commitment to enhancing R&D investment[1]. - Management expenses rose by 59.76% to 18.44 million yuan, primarily due to increased employee compensation and the consolidation of a new subsidiary[1]. - Cash payments to employees increased by 93.67% to 56.59 million yuan, attributed to higher sales bonuses[18]. - The company paid CNY 56,594,612.68 in employee compensation, significantly higher than CNY 29,222,545.96 in the previous year[51]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,725[11]. - The largest shareholder, Yan Jinyuan, holds 32.27% of the shares, with 47,136,790 shares, of which 35,352,592 are pledged[11]. - The company plans to grant 2.52 million restricted stocks to 130 incentive targets as part of its 2021 incentive plan[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,599,856,209.83, a slight decrease of 0.45% from CNY 1,607,164,079.53 at the end of the previous year[7]. - The net assets attributable to shareholders increased by 2.68% to CNY 942,525,836.28 from CNY 917,930,478.94 at the end of the previous year[7]. - Current liabilities decreased to CNY 360,656,980.24 from CNY 394,650,575.02, indicating improved liquidity management[35]. - The company's total liabilities were CNY 542,641,903.73, down from CNY 574,332,071.42, reflecting a reduction in financial obligations[35]. - Total equity increased from CNY 863,324,951.78 to CNY 883,794,038.14[42]. Government Support and Funding - The company received government subsidies amounting to CNY 1,393,577.14 during the reporting period[8]. - The total amount of funds raised was 212.68 million yuan, with 5.51 million yuan invested in the current quarter[24]. - The total amount of raised funds for the project "Blood Purification Industry Base and R&D Center" is 15,365.75 million yuan, with a cumulative investment of 3,049.25 million yuan, achieving 19.84% of the planned progress as of December 31, 2023[25]. - The company has utilized 5,902 million yuan for working capital, achieving 100% of the planned investment[25]. Operational Highlights - The health monitoring segment generated sales revenue of 87.53 million yuan, up 1.23% year-on-year, while the nephrology medical segment saw sales revenue of 153.66 million yuan, an increase of 14.39%[19]. - Total operating revenue for Q1 2021 was CNY 242,726,398.90, an increase from CNY 222,377,646.65 in the previous period[41]. - Total operating costs for Q1 2021 were CNY 217,056,279.99, up from CNY 172,121,700.98 in the previous period, with operating costs specifically rising from CNY 124,546,059.52 to CNY 158,381,413.76[42]. Miscellaneous - The company has approved the absorption merger of its wholly-owned subsidiaries to optimize management structure and reduce costs[26]. - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[27][28]. - The company has not reported any significant changes in the feasibility of projects or the expected benefits during the reporting period[25]. - The company did not undergo an audit for the first quarter report[57]. - The new leasing standards were not applicable for the company starting in 2021[56].